Moderate hyperprolactinemia is associated with survival in patients with acute graft-versus-host disease after allogeneic stem cell transplantation

Figures & data

Table 1. Baseline clinical and relevant hematological data in healthy volunteers (group 1) and in patients with allo-HSCT (group 2) with and without graft-versus-host disease (GVHD+ and GVHD−) and in their donors (group 3)

	Sex	Age (years)	BMI* (kg/m^2)	Diagnosis	CD34+ (×10^6/kg)	GVHD (days after transplant)	Chimerism (%)
Group 1
1	M	25	23.1	Healthy	–	–
2	M	34	22.1	Healthy	–	–
3	M	24	25.9	Healthy	–	–
4	M	22	25.7	Healthy	–	–
5	M	48	24.9	Healthy	–	–
6	M	26	27.2	Healthy	–	–
7	M	23	22.4	Healthy	–	–
8	M	52	28.1	Healthy	–	–
9	M	20	20.6	Healthy	–	–
10	M	27	24.6	Healthy	–	–
Mean ± SD		30.1 ± 11.2	24.5 ± 2.3
Group 2
1	M	44	24.2	MM^†	3.9	+43	95
2	M	27	21.0	SAA^‡	4.0	+35	92
3	M	51	31.1	MF^§	1.3	–	100
4	M	35	28.8	CML^¶	2.1	+100	100
5	M	28	18.7	NHL**	1.2	+85	80
6	M	59	27.9	MM^†	4.3	–	91
7	M	33	27.4	SAA^‡	3.8	–	80
8	M	19	31.0	AML^††	4.5	–	92
9	F	31	23.4	CML^¶	2.5	–	14
10	F	14	20.1	AML^††	1.7	–	100
Mean ± SD		34.1 ± 13.8	25.4 ± 4.6
Group 3
1	F	53	19.7	Donor	–	–
2	F	27	23.0	Donor	–	–
3	F	49	29.6	Donor	–	–
4	M	22	37.1	Donor	–	–
5	F	12	17.5	Donor	–	–
6	F	21	21.3	Donor	–	–
7	M	41	31.8	Donor	–	–
8	F	48	18.2	Donor	–	–
9	F	15	24.5	Donor	–	–
10	M	40	31.4	Donor	–	–
Mean ± SD		32.8 ± 15.1	25.4 ± 6.6

*Body mass index.

^†Multiple myeloma.

^‡Severe aplastic anemia.

^§Mycosis fungoides.

^¶Chronic myelogenous leukemia.

**Non-Hodgkin's lymphoma.

^††Acute myelogenous leukemia.

Table 2. Serum PRL concentrations both basal and during the metoclopramide test (AUC-PRL) in the pre- and post-transplant period in healthy controls (group 1), patients (group 2), and their donors (group 3)

	Pre-transplant		Post-transplant
	Basal serum PRL (ng/ml)	AUC-PRL (ng/ml/120 minutes)	Basal serum PRL (ng/ml)			AUC-PRL (ng/ml/120 minutes)
			Day +14	Day +30	Day +100	Day +100
Groups
1 Control	5.8 ± 1.2	4242 ± 429	–	–	–	–
2 All patients	11.02 ± 1.1*	7231 ± 1097	–	–	–	–
3 All donors	6.8 ± 0.78	13 537 ± 2552^†	–	–	–	–
Patient ‘future’ GVHD(+)	13.1 ± 1.8^‡	8301 ± 1495	15.2 ± 4.5^§	18.2 ± 3.3^§	29.3 ± 11.6^§	6538 ± 960
Patient ‘future’ GVHD(−)	9.3 ± 0.89	6374 ± 1606^¶	7.4 ± 0.9	6.4 ± 1.2	7.2 ± 0.9	5905 ± 425
Donor ‘future’ GVHD(+)	4.7 ± 0.48**	13467 ± 4791	–	–	–	–
Donor ‘future’ GVHD(−)	8.4 ± 1.1	13 593 ± 3111	–	–	–	–

Note: Values are mean ± SEM.

*Vs. groups 1 and 3 P ≤ 0.01.

^†Vs. groups 1 (P = 0.01) and 2 (P = 0.05).

^‡Vs. Donor ‘future’ GVHD(+) P < 0.001.

^§Vs. Host ‘future’ GVHD(−) P ≤ 0.05.

^¶Vs. Donor ‘future’ GVHD(−) P = 0.05.

**Vs. Donor ‘future’ GVHD(−) P = 0.01.

Figure 1. Basal Th1 type of cytokines before transplant in donors of patients who later on developed GVHD(+) and those who did not (−), as well as their corresponding recipients (mean ± SEM).

Figure 2. Mean values of Th1 and Th2 cytokines and PRL serum concentrations from the day of transplant up to day 100 after transplant, both in patients who did develop GVHD (+) and in those who did not develop GVHD (−).